Generation Bio (NASDAQ:GBIO – Get Free Report) and Bio-Path (NASDAQ:BPTH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.
Earnings & Valuation
This table compares Generation Bio and Bio-Path’s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Generation Bio | $5.90 million | 30.78 | -$126.61 million | ($2.55) | -1.07 |
Bio-Path | N/A | N/A | -$16.08 million | N/A | N/A |
Bio-Path has lower revenue, but higher earnings than Generation Bio.
Insider and Institutional Ownership
Volatility and Risk
Generation Bio has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
Profitability
This table compares Generation Bio and Bio-Path’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Generation Bio | -1,696.87% | -82.33% | -46.73% |
Bio-Path | N/A | -1,037.30% | -337.80% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Generation Bio and Bio-Path, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Generation Bio | 0 | 4 | 2 | 0 | 2.33 |
Bio-Path | 0 | 0 | 1 | 0 | 3.00 |
Generation Bio presently has a consensus price target of $8.00, suggesting a potential upside of 193.04%. Bio-Path has a consensus price target of $20.00, suggesting a potential upside of 920.41%. Given Bio-Path’s stronger consensus rating and higher probable upside, analysts clearly believe Bio-Path is more favorable than Generation Bio.
Summary
Generation Bio beats Bio-Path on 7 of the 11 factors compared between the two stocks.
About Generation Bio
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Bio-Path
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.